Shaping Therapeutic Development With Cutting-Edge CRISPR Nucleases: Featuring eSpOT-ON

Discover Synthego's latest engineered nuclease, eSpOT-ON, and explore its superior on-target/off-target fidelity compared to other Cas9 variants and its therapeutic potential in treating familial hypercholesterolemia. Learn how eSpOT-ON boosts editing efficiency and how to integrate it into your research.

The session also covers crucial factors for therapeutic nuclease selection, including licensing, high-fidelity performance, and gene editing flexibility. We highlight the benefits of single-source procurement for CRISPR gRNAs and nucleases (from RUO to GMP), showcasing Synthego's GMP SpCas9 nuclease. This unified approach, backed by robust documentation and QC/QA, streamlines regulatory compliance and accelerates your path to clinical success.

By the end, you'll grasp how Synthego's nuclease portfolio empowers CRISPR-based cell and gene therapy, offering optimal solutions for therapeutic breakthroughs.

Key Learning Objectives:

• Unlock the therapeutic advantages of eSpOT-ON.
• Master nuclease selection for therapeutic applications.
• Understand the critical role of single-vendor sourcing from RUO to GMP.